Related Experiment Video
Updated: Oct 17, 2025
A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
An Application of the Patient Rule-Induction Method to Detect Clinically Meaningful Subgroups from Failed Phase III
1Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit MI, USA.
Background:
Phase III superiority clinical trials have negative results (new treatment is not statistically better than standard of care) due to a number of factors, including patient and disease heterogeneity. However, even a treatment regime that fails to show population-level clinical improvement will have a subgroup of patients that attain a measurable clinical benefit.
Objective:
The goal of this paper is to modify the Patient Rule-Induction Method to identify statistically significant subgroups, defined by clinical and/or demographic factors, of the clinical trial population where the experimental treatment performs better than the standard of care and better than observed in the entire clinical trial sample.
Results:
We illustrate this method using part A of the SUCCESS clinical trial, which showed no overall difference between treatment arms: HR (95% CI) = 0.97 (0.78, 1.20). Using PRIM, we identified one subgroup defined by the mutational profile in BRCA1 which resulted in a significant benefit for adding Gemcitabine to the standard treatment: HR (95% CI) = 0.59 (0.40, 0.87).
Conclusion:
This result demonstrates that useful information can be extracted from existing databases that could provide insight into why a phase III trial failed and assist in the design of future clinical trials involving the experimental treatment.
Insights
Even when a new treatment fails overall in clinical trials, specific patient subgroups may still benefit. Our study identified a subgroup with BRCA1 mutations who significantly benefited from Gemcitabine, offering insights for future trial designs.
Area of Science:
- Clinical trial analysis
- Biostatistics
- Oncology
Background:
- Phase III trials often yield negative results due to patient and disease heterogeneity.
- Subgroups of patients may still experience clinical benefit even if the overall trial fails.
Purpose of the Study:
- To adapt the Patient Rule-Induction Method (PRIM) for identifying significant patient subgroups.
- To find subgroups where experimental treatments outperform standard care and the general trial population.
Main Methods:
- Utilized the Patient Rule-Induction Method (PRIM).
- Applied to Part A of the SUCCESS clinical trial data.
Main Results:
- The overall trial showed no significant difference between treatment arms (HR: 0.97 [0.78, 1.20]).
- PRIM identified a subgroup with BRCA1 mutations benefiting from Gemcitabine (HR: 0.59 [0.40, 0.87]).
Conclusions:
- Subgroup analysis of existing trial data can reveal valuable insights.
- This approach can explain Phase III trial failures and inform future clinical trial design.
More Related Videos
05:16Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
Published on: June 10, 2025
07:13Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model
Published on: April 18, 2025
Related Concept Videos
01:11Clinical Trials: Overview
01:16Clinical Trials
There are four phases in a clinical trial. A phase one...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
01:20Comparing the Survival Analysis of Two or More Groups
01:24Kaplan-Meier Approach
01:15Bioavailability Study Design: Healthy Subjects Versus Patients